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Aim. To review the prevalence of gestational diabetes mellitus (GDM) in Eastern and Southeastern Asia. Methods. We
systematically searched for observational studies on GDM prevalence from January 2000 to December 2016. Inclusion criteria
were original English papers, with full texts published in peer-reviewed journals. The quality of included studies was evaluated
using the guidelines of the National Health and Medical Research Council, Australia. Fixed effects and random effects models
were used to estimate the summary prevalence of GDM and the corresponding 95% confidence intervals (CI). Results. A total
of 4415 papers were screened, and 48 studies with 63 GDM prevalence observations were included in the final review. The
pooled prevalence of GDM was 10.1% (95% CI: 6.5%–15.7%), despite substantial variations across nations. The prevalence of
GDM in lower- or upper-middle income countries was about 64% higher than in their high-income counterparts. Moreover,
the one-step screening method was twice more likely to be used in diagnosing GDM when compared to the two-step
screening procedure. Conclusions. The prevalence of GDM in Eastern and Southeastern Asia was high and varied among and
within countries. There is a need for international uniformity in screening strategies and diagnostic criteria for GDM.
1. Introduction
Gestational diabetes mellitus (GDM), which is defined as
diabetes diagnosed in the second and third trimesters of
pregnancy [1], has emerged as a global public health concern
[2]. It has been associated with short-term and long-term
adverse health outcomes for both mothers and their new-
borns [3]. Women with GDM are known to have decreased
quality of life and increased risks of caesarean section, gesta-
tional hypertension, preeclampsia, and type 2 diabetes [4–7].
In babies, GDM has been found to be associated with macro-
somia or larger than normal gestational-aged infants, neona-
tal hypoglycemia, and type 2 diabetes mellitus later in life
[6, 8, 9]. As such, it is important to understand the burden
of GDM in various parts of the world to provide country-
specific information to help inform on policy and planning.
The global prevalence of GDM varies widely, from 1%
to 28%, depending on population characteristics (e.g.,
maternal age, socioeconomic status, race/ethnicity, or body
composition), screening methods, and diagnostic criteria
[10]. In addition, as with the common form of type 2 dia-
betes [11], GDM can also be influenced by genetic factors,
which may differently affect disease prevalence among
populations [12]. To date, at least 8 associations have
developed their own diagnostic criteria for GDM, namely,
the American Diabetes Association (ADA 2004, 2007, 2010,
and 2012),AustralianDiabetes inPregnancy Society (ADIPS),
Carpenter-Coustan (CC), International Association of the
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Diabetes and Pregnancy Study Groups (IADPSG), Inter-
national Classification of Diseases (ICD), Japan Society
of Obstetrics and Gynecology (JSOG), National Diabetes
Data Group (NDDG), and World Health Organization
(WHO 1998, 1999, 2006, and 2013) [13, 14]. Data in high-
income countries (HICs) ranges from 0.6% to 27.5% [15],
and those in low- and middle-income countries are in the
range of 0.4 and 24.3% [16]. Regional differences exist
regarding the distribution of GDM, such as Africa and
Asia, after adjusting the data with prevalence reports being
0%–13.9% and 1.6%–17.8%, respectively [17, 18].
Asia is the largest and most populated continent (60% of
the world’s population), with an increasing prevalence of
GDM [19]. While maternal overweight/obesity is an estab-
lished risk factor for GDM [20], particularly in HICs, recent
reviews have found that the prevalence of GDMmay be even
higher among lean populations than those with a larger body
size [2]. This is consistent with the developmental origins of
adult disease hypothesis (DOHAD) as undernutrition in the
first 1000 days is associated with later diabetes [21–24]. The
Eastern and Southeastern subregions include 18 countries,
with more than 30% of the Asian population [25] and con-
tributing approximately 80% to the Asian economy [26].
Given the rapid socioeconomic and nutrition transition and
the increasing prevalence of GDM in Asia [19, 27], it is of
public health importance to provide an overview of this con-
dition in Eastern and Southeastern Asia. However, accessible
and systematically organized estimates of GDM prevalence
in this subregion are lacking. Moreover, the lack of unifor-
mity in screening methods, definition, and diagnostic criteria
for GDM makes it difficult to compare the prevalence of
GDM between and within countries. The aim of this study
was to undertake a systematic review and meta-analysis of
the prevalence and associated risk factors of GDM in selected
countries of Eastern and Southeastern Asia.
2. Methods
The present review was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement [28] and theMeta-analysis Of Observa-
tional Studies in Epidemiology (MOOSE) protocols [29].
2.1. Search Strategy. The databases (PubMed, Embase, and
Scopus) were used to search relevant articles with the follow-
ing key words: “gestational diabetes mellitus,” “GDM,”
“hyperglycemia in pregnancy,” “gestational hyperglycemia,”
or “diabetes in pregnancy” as well as “name of country” in
Eastern and Southeastern Asia. The websites of the World
Health Organization (WHO) and International Diabetes
Federation were also reviewed to extend our search results.
Then the reference lists of included articles were assessed to
identify further relevant studies.
2.2. Inclusion Criteria. Studies that met the following criteria
were retrieved for assessment: (1) being conducted in Eastern
and Southeastern Asian countries classified by the United
Nations Statistics Division [30]; (2) being published in
English language journals between January 1, 2000, and
December 31, 2016; (3) reported primary results (i.e., original
studies); (4) provided the prevalence of GDM and associated
95% confidence interval (CI) or total of participants and
number of GDM events; and (5) had a sample size of at least
1000 and 50 GDM cases. When multiple publications were
derived from analyses of the same or overlapping samples,
we used data from the largest or most recent results only.
2.3. Study Selection. Relevant papers identified from the
aforementioned databases and websites were imported
into an EndNote X7.5, and duplicates were removed. Two
reviewers independently screened the titles and abstracts
for potentially eligible articles based on the inclusion criteria.
If a paper contained insufficient information on GDM in the
title and/or abstract, the full text was retrieved for further
assessment and any disagreement between the two reviewers
was resolved through discussion. Finally, the full text of rele-
vant studies was reviewed.
2.4. Quality Assessment and Data Extraction. The guidelines
of the National Health and Medical Research Council were
used to assess the quality of searched articles by two indepen-
dent investigators [31]. Only articles that meet the level III of
evidence were included and analysed in this review. An
extraction form was developed in Excel to record data from
selected papers by one reviewer, and the completeness and
accuracy of extracted data were verified by a second reviewer.
The following characteristics were extracted from each study:
first author, country, year of publication, year of survey, set-
ting, gestational age, screening procedure (one and/or two
steps), sample size, GDM cases, prevalence of GDM (includ-
ing percentage and 95% CI), and diagnostic criteria for
GDM. If 95% CIs were not reported, they were calculated
based on the sample size and observed proportion of GDM
in each selected study [32]. Since we only collected published
studies, ethical approval was not required for this work.
2.5. Data Analysis. Diagnostic criteria were aggregated into 8
clusters due to some similarities: (1) JSOG, (2) NDDG, (3)
ADA 2004/ADA 2010, (4) ICD10, (5) ADA 2007/CC, (6)
WHO 1998–2006, (7) ADA 2012/IADPSG/WHO 2013; and
(8) ADIPS98. The prevalences of GDM, with 95% CI, were
grouped according to the different diagnostic criteria to per-
form meta-analyses. The summary prevalence (95% CI)
regardless of and by each diagnostic criteria was calculated
using the random effects model of the DerSimonian and
Laird method [33] to allow for the possibility of real differ-
ences in the distribution of GDM between studies that are
not solely resulted from sampling error. The heterogeneity
among studies was tested with the I2 index (low is <25%,
moderate 25%–50%, and high> 50%), which describes the
percent of total variation contributed by between-study vari-
ations [34]. The overall prevalence of GDM (95% CI) by each
group of diagnostic criteria was depicted graphically in forest
plots. Statistically significant heterogeneity was considered
present at P < 0 1 and I2> 50% [35]. In addition, subgroup
analysis according to lower- or upper-middle income coun-
tries (LMICs) or HICs, type of GDM screening, and individ-
ual country under study was performed to understand the
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impact of economic development and geographical location
on the prevalence of GDM. The summary prevalence of
GDM for each study that used more than one diagnostic cri-
terion was pooled using a fixed effects model. All analyses
were performed using Stata 13.1 (StataCorp LP, College
Station, TX).
3. Results
3.1. Description of Included Studies. Figure 1 shows the flow
diagram of our systematic literature search. The initial search
identified 5697 publications, and after the removal of dupli-
cate records (n = 1282), 4415 were retrieved for preliminary
assessment. Of these, 120 were potentially relevant after
title and abstract screening, and thus, their full texts were
obtained and evaluated against the inclusion criteria, result-
ing in 48 studies reported in 63 observations. No papers were
retrieved from the reference list. Of 48 studies, one paper
reported four values of GDM prevalence by using four
diagnostic criteria [36], 12 papers had two values of GDM
prevalence by comparing two different diagnostic criteria or
screening types [37–48], and 35 papers only used one diag-
nostic criterion to estimate GDM prevalence [49–83].
3.2. Characteristics of Included Studies. The main characteris-
tics of the included studies are described in the Supplemental
Table (available here). Between the years 2000 and 2016, 48
articles were published with a total sample of 3,594,803 preg-
nant women (range: 1038–1,824,913) in 7 countries. Of the
48 studies, 21 were conducted in China [41–43, 45, 48–64],
8 in the Republic of Korea [65, 68, 70–72, 74, 75, 77], 6 in
Thailand [37, 46, 79–81, 83], five in Japan [39, 47, 73,
76, 78], five in Taiwan (China) [38, 44, 66, 67, 69], one in
Malaysia [82], one in Singapore [40], and one in Vietnam
[36]. Two-thirds of the studies (n = 32) used a two-step
screening procedure, that is, women underwent a 1-hour glu-
cose challenge test (GCT) and a 3-hour glucose tolerance test
(GTT) if GCTwere abnormal. To perform these tests, women
were required to drink 50 g of glucose and 75 or 100 g of glu-
cose for GCT and GTT, respectively. Over one-quarter of
studies (n = 13) followed a single-step screening, where all
pregnant women were given a 75 g GTT. Three studies did
not specify the screening method used [56, 71, 75]. A total
of 20 studies used IADPSG, the 2010 ADA, or the 2013
WHO standards as the GDM diagnostic criteria. The number
of studies that employed CC or the 2007 ADA, NDDG,WHO
(1998, 1999, and 2006) was 13, 12, and 10, respectively. The
remaining 8 studies applied other criteria (see Supplemental
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Figure 1: PRISMA flow diagram of selected studies.
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Table). All studies included in the present review met the
level III of evidence of the National Health and Medical
Research Council in Australia [31].
3.3. Prevalence of GDM. The overall mean prevalence of
GDM, regardless of diagnostic standards, was 10.07 (95%
CI: 6.47–15.68) (Table 1). Figure 2 depicts the prevalence
of GDM across 8 diagnostic groupings. The highest preva-
lence of GDM was observed for studies using the IADPSG,
ADA 2012, or WHO 2013 criteria (13.77%) while the lowest
data was found among Japanese reports that employed JSOG
criteria (2.80%). Between that range, the summary preva-
lence of GDM according to NDDG, ADA 2004 or ADA
2010, ADA 2007 or CC, and WHO (1998, 1999, or 2006)
recommendations was 5.24%, 6.59%, 8.54%, and 9.40%,
respectively. Only two single data points for GDM preva-
lence were reported using either ICD 10 [75] or ADIPS
1998 [36], with the respective prevalences being 7.53% and
20.82%, respectively (Table 1). With the exception of studies
employing JSOG, there was considerable heterogeneity of
GDM prevalence among studies assessed based on various
criteria; a measure of heterogeneity varied from 98.5% to
99.8% (P < 0 001).
3.4. Prevalence of GDM by Income and Diagnostic Criteria.
Overall, the prevalence of GDM was higher in LMICs than
HICs, 10.84% versus 6.66%, respectively (Table 1). Except
for pooled GDM prevalence according to WHO (1998,
1999, or 2006) criteria, the summary estimates of GDM
prevalence based on other diagnostic criteria were greater
in LMICs than in HICs. Notably, the prevalence using
the most popular criteria, that is, ADA 2012, IADPSG,
or WHO 2013, was over twofold higher in the former
Table 1: Pooled prevalence and 95% confidence interval of gestational diabetes according to the income group, screening type, and country.
Studies Subjects Prevalence Lower 95% CI Upper 95% CI I2 Pheterogeneity
Income level
High
JSOG 2 3877 2.80 2.31 3.39 0.00% 0.411
NDDG 4 35,400 4.21 2.15 8.26 99.30% <0.001
ICD10 1 1,306,281 7.53 7.51 7.56 — —
ADA 2007/CC 9 1,880,183 7.38 6.03 9.03 98.90% <0.001
WHO 1999–2006 2 2272 15.37 13.89 17.02 — —
ADA 2012/IADPSG/WHO 2013 6 16,237 7.48 4.74 11.80 98.60% <0.001
Subtotal 24 3,244,250 6.66 4.40 10.09 98.30% <0.001
Lower- or upper-middle
NDDG 8 79,487 5.83 4.31 7.90 99.10% <0.001
ADA 2004/ADA 2010 4 28,342 6.59 4.40 9.86 98.50% <0.001
ADA 2007/CC 4 21,259 11.85 4.94 28.42 99.80% <0.001
WHO 1999–2006 8 183,545 8.57 5.23 14.06 99.90% <0.001
ADA 2012/IADPSG/WHO 2013 14 113,656 17.56 15.07 20.47 99.20% <0.001
ADIPS98 1 2772 20.82 19.34 22.40 — —
Subtotal 39 429,061 10.84 7.35 15.99 94.40% <0.001
Type of screening
One step 13 95,638 15.71 13.88 17.77 98.90% <0.001
Two-step 32 338,825 7.15 5.63 9.08 99.70% <0.001
Unspecified 3 3,132,329 7.83 7.39 8.29 99.70% <0.001
Country
Mainland China 21 282,086 11.91 8.96 15.83 99.90% <0.001
Japan 5 12,596 6.08 3.49 10.62 98.70% <0.001
Korea 8 3,180,515 7.12 6.74 7.53 99.60% <0.001
Malaysia 1 1538 11.83 10.30 13.60 — —
Singapore 1 1136 18.93 16.74 21.40 — —
Taiwan 5 30,944 6.51 4.45 9.54 99.0% <0.001
Thailand 6 55,205 6.10 4.39 8.48 98.8% <0.001
Vietnam 1 2772 20.06 19.28 20.87 — —
All 48 3,566,792 10.07 6.47 15.68 99.3% <0.001
—: not applicable; ADA: American Diabetes Association; ADIPS: Australian Diabetes in Pregnancy Society; CC: Carpenter-Coustan; IADPSG: International
Association of the Diabetes and Pregnancy Study Groups; ICD: International Classification of Diseases; JSOG: Japan Society of Obstetrics and Gynecology;
NDDG: National Diabetes Data Group; WHO: World Health Organization.
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when compared with the corresponding figure in the latter
(17.56% versus 7.48%) (Table 1).
3.5. Prevalence of GDM by Screening Method. The mean
prevalence of GDM derived using one-step screening and
two-step screening was 15.71% (95% CI: 13.88–17.77%)
and 7.15% (95%CI: 5.63–9.08%), respectively; there was sub-
stantial heterogeneity among studies using either the one-
step screening method or the two-step screening method
(I2 > 98% and P < 0 001) (Table 1).
Note: weights are from random effects analysis
JSOG
Morikawaet al. 2010 [39]
Nobumoto et al. 2015 [47]
Subtotal (I2 = 0.0%, P = 0.411)
NDDG
Jang et al. 2003 [65]
Sunsaneevithayakul et al. 2003 [37]
Chou et al. 2010 [38]
Fan et al. 2006 [59]
Wang et al. 2013 [69]
Srichumchit et al. 2015 [83]
Ruangvutilert et al. 2010 [81]
Sunsaneevithayakul et al. 2003 [37]
Punthumapol et al. 2008 [80]
Chuang CM et al. 2012 [67]
Luengmettakul et al. 2015 [46]
Boriboonhirunsarn et al. 2004 [79]
Subtotal (I2 = 99.1%, P = 0.000)
ADA 2004/ADA 2010
Yang et al. 2009 [60]
Tran et al. 2013 [36]
Shang et al. 2014 [42]
Shang et al. 2014 [43]
Subtotal (I2 = 98.5%, P = 0.000)
ADA 2007/CC
Luengmettakul et al. 2015 [46]
Chou et al. 2010 [38]
Hung et al. 2015 [44]
Park et al. 2013 [68]
Heo et al. 2015 [72]
Cho et al. 2015 [71]
Lin et al. 2009 [66]
Jung et al. 2015 [74]
Park et al. 2016 [77]
Chang et al. 2014 [63]
Liao et al. 2014 [41]
Yang et al. 2013 [70]
Wang et al. 2011 [61]
Subtotal (I2 = 99.7%, P = 0.000)
WHO 1998–2006
Yang et al. 2002 [58]
Zhang et al. 2011 [62]
Liu et al. 2014 [64]
Leng et al. 2015 [45]
Chong et al. 2014 [40]
Tan et al. 2011 [82]
Peng et al. 2015 [51]
Zhu et al. 2015 [48]
Chong et al. 2014 [40]
Tran et al. 2013 [36]
Subtotal (I2 = 99.8%, P = 0.000)
ADA 2012/IADPSG/WHO 2013
Shimodaira et al. 2016 [78]
Limura et al. 2015 [73]
Morikawa et al. 2010 [39]
Leng et al. 2015 [45]
Shang et al. 2014 [43]
Hung et al. 2015 [44]
Nobumoto et al. 2015 [47]
Ohara et al. 2016 [76]
Xu et al. 2016 [56]
Li et al. 2015 [50]
Wei et al. 2015 [53]
Zhu et al. 2015 [48]
He et al. 2015 [49]
Wang et al. 2015 [52]
Shang et al. 2014 [42]
Tran et al. 2013 [36]
Ye et al. 2016 [57]
Wei et al. 2016 [55]
Liao et al. 2014 [41]
Li et al. 2016 [54]
Subtotal (I2 = 99.2%, P = 0.000)
Study
Japan
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Korea
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China
Taiwan
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Taiwan
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636
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Figure 2: Forest plots presenting the prevalence of gestational diabetes for individual studies and the corresponding pooled prevalence for
studies combined according to diagnostic criteria in Eastern and Southeastern Asia. Bars and diamonds indicate 95% confidence interval
(CI). The size of each square corresponds to the weight of the study in the meta-analysis using the Der Simonian and Laird method. ADA:
American Diabetes Association; CC: Carpenter-Coustan; IADPSG: International Association of the Diabetes and Pregnancy Study
Groups; JSOG: Japan Society of Obstetrics and Gynecology; NDDG: National Diabetes Data Group; WHO: World Health Organization.
5Journal of Diabetes Research
3.6. Prevalence of GDM by Country. There was variation in
the overall prevalence of GDM, with Vietnam and Singa-
pore showing the highest rates (20.06% and 18.93%, resp.).
While mainland China and Malaysia had a comparable
prevalence of GDM (11.91% and 11.83%), the remaining
countries (Japan, Korea, Taiwan, and Thailand) had a
GDM prevalence of less than 8.0%. It should be noted that
mainland China accounted for nearly 50% of the total
studies (n = 21) (Table 1).
4. Discussion
The present review included 48 studies with more than three
and a half million participants from 7 countries in Eastern
and Southeastern Asia, showing a wide variation in the over-
all prevalence of GDM. The pooled prevalence of GDM was
approximately 10%, with a higher estimate in LMICs than
in HICs. The discrepancy in the overall estimate also existed
according to diagnostic criteria and countries. The most
widely used criteria were ADA 2012, IADPSG, or WHO
2013, resulting in a pooled prevalence of GDM of 14% while
only a limited number of studies used ADIP 1998, ICD 10,
JSOG, ADA 2004, or ADA 2010. The highest prevalence of
GDM was found in Vietnam and Singapore, where approxi-
mately one in five women were diagnosed with GDM,
followed by mainland China and Malaysia where about one
in 9 women had GDM. The remaining countries had no
more than one in 14 women with GDM. To the best of our
knowledge, this is the first study that systematically synthe-
sised data on the prevalence of GDM in important subre-
gions of Asia, Eastern and Southeastern, and provided
accessible evidence to formulate locally feasible strategies
for effective and efficient prevention of GDM in Asia.
Overall, approximately one in 10 pregnant women in
Eastern and Southeastern Asia had GDM. This finding is
higher than African countries, where the average prevalence
of GDM is about 6.0% [17]. Similarly, our data is greater than
results reported in Western countries including Europe, US,
and Australia, with the prevalence of GDM being 5.4%,
9.2%, and 5.7%, respectively [84–86]. We have no clear
reason for such a discrepancy, but we speculate that it
may be due to socioeconomic, racial/ethnic, or lifestyle dis-
parities. For instance, Asian women were reportedly having
a higher risk of GDM compared with their Caucasian,
African-American, and Hispanic counterparts [87]. This
observation suggests that the development of GDM may
be shaped by early-life exposure to poor nutrition, that is,
under- or overnutrition, and/or epigenetics according to
the DOHAD theory [88]. Another factor may be the dif-
ferent screening regimes and testing methods that will be
discussed below.
The lack of consensus regarding the use of diagnostic
criteria for GDM is largely attributable to the heterogene-
ity of GDM prevalence. Of diverse diagnostic criteria such
as NDDG [89], CC [90], ADA [91], and WHO [92], the
IADPSG criteria based on the Hyperglycemia and Adverse
Pregnancy Outcome Study (HAPO) has recently become
more accepted [93]. Indeed, the use of IADPSG criteria
may produce an estimated prevalence of GDM two to
threefold even up to 7-fold higher than other criteria [13,
94]. In a Brazilian study, for instance, the prevalence of
GDM was only 2.3% and 7.1% according to ADA 2010 and
WHO 1999, respectively, but it increased to 18.0% following
the IADPSG criteria [94]. An alternative explanation for the
variation in GDM prevalence may be ascribed to different
screening methods, that is, the one-step or two-step
approach. Similar to our review, a recent meta-analysis of
40 studies in Europe reported that the one-step screening
method resulted in a higher prevalence of GDM compared
with the two-step procedure [86]. Although a one-step
screening type is simpler, less laborious, and of low lost, it
typically overestimates the prevalence of GDM [95]. How-
ever a two-step screening method is more accurate and could
accordingly reduce personal and societal costs despite its
inconvenience for patients and increased workload for
healthcare professionals [96]. Given the lack of international
consensus in screening and diagnostic methods for GDM, it
is imperative to develop a standardised approach to allow
for comparison of GDM burdens worldwide.
The high prevalences of GDM in less wealthy countries
reviewed here are consistent with studies from other parts
of Asia and Africa [17, 18]. Likewise, around 90% of cases
of hyperglycemia during pregnancy occur in low- and
middle-income nations as reported by the International Dia-
betes Federation in 2015 [27]. This discrepancy may be asso-
ciated with limited access to maternal health care and/or low
socioeconomic status in low- and middle-income economies
[27, 97, 98]. It is evident from this review that the prevalence
of GDM in Vietnam, a lower-middle income country, at
least tripled the corresponding data in HICs such as Japan,
Taiwan, and South Korea. It can also be speculated that the
difference in lifestyle factors (e.g., diet and physical activity),
acculturation, and urbanisation may explain the variation in
GDM prevalence between the two aforementioned country-
income groups [99]. This finding implies that improvement
of socioeconomic conditions may contribute to the preven-
tion of GDM.
On the other hand, more epidemiological studies on
GDM in the remaining countries of Eastern and South-
eastern Asian regions including Mongolia, Indonesia,
Philippines, Myanmar, Cambodia, and Laos need to be con-
ducted to add information to the current evidence. These
studies should be performed in both urban and rural popula-
tions in order to compare and evaluate the effects of urbani-
sation on GDM in particular and public health in general.
The present review has the advantages of a large sample
size with studies involving over three and a half million
women, using different methods for screening and diagnosis
of GDM and consistency of method, quality, and focus.
There are several limitations that need to be considered when
interpreting the results of this work. Our review indicated
substantial heterogeneity of GDM prevalence across studies,
making direct comparison difficult. Such variation may be
attributable to the potential influence of screening proce-
dures (i.e., selective or universal) for GDM and its diagnostic
criteria, population characteristics, or other socioenviron-
mental factors. Nonetheless, those possible modifiers were
not taken into account in this review due to the lack of data
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available from included studies. In addition, the inclusion of
only English publications may have resulted in publication
bias. Our review did not address GDM situations in other
countries in the region including Indonesia, Philippines,
Myanmar, Cambodia, and Laos due to the lack of data, and
thus, the findings may not be generalisable to the whole East-
ern and Southeastern Asia.
5. Conclusion
A large-scale review of literature shows that around one in 10
pregnant women in Eastern and Southeastern Asia had GDM
and the number of women with GDM varied substantially
between and within countries. The prevalence of GDM was
highest according to ADA 2012, IADPSG, or WHO 2013 cri-
teria, greater following a one-step screening procedure and
higher in LMICs. The findings suggest the need for develop-
ing an international uniformity regarding screening and
diagnostic methods for GDM.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Authors’ Contributions
Cong Luat Nguyen and Ngoc Minh Pham designed the
study and wrote the manuscript. Cong Luat Nguyen sys-
tematically searched the literature and extracted data. Ngoc
Minh Pham reviewed the included studies and conducted
statistical analyses. Colin W. Binns and Andy H. Lee criti-
cally commented and substantially revised the manuscript.
Dat Van Duong contributed to literature review and discus-
sion. All authors participated in drafting the manuscript
and approved the final version.
Supplementary Materials
Supplemental Table: characteristics of selected studies.
(Supplementary Materials)
References
[1] American Diabetes Association, “2. Classification and diag-
nosis of diabetes,” Diabetes Care, vol. 38, Supplement 1,
pp. S8–S16, 2015.
[2] L. Guariguata, U. Linnenkamp, J. Beagley, D. R. Whiting, and
N. H. Cho, “Global estimates of the prevalence of hyperglycae-
mia in pregnancy,” Diabetes Research and Clinical Practice,
vol. 103, no. 2, pp. 176–185, 2014.
[3] D. Farrar, M. Simmonds, M. Bryant et al., “Hyperglycaemia
and risk of adverse perinatal outcomes: systematic review
and meta-analysis,” BMJ, vol. 354, article i4694, 2016.
[4] C. Kim, K. M. Newton, and R. H. Knopp, “Gestational diabetes
and the incidence of type 2 diabetes: a systematic review,” Dia-
betes Care, vol. 25, no. 10, pp. 1862–1868, 2002.
[5] Y. Yogev, E. M. J. Xenakis, and O. Langer, “The association
between preeclampsia and the severity of gestational diabetes:
the impact of glycemic control,” American Journal of Obstet-
rics and Gynecology, vol. 191, no. 5, pp. 1655–1660, 2004.
[6] HAPO Study Cooperative Research Group, B. E. Metzger,
L. P. Lowe et al., “Hyperglycemia and adverse pregnancy out-
comes,” The New England Journal of Medicine, vol. 358, no. 19,
pp. 1991–2002, 2008.
[7] D. Marchetti, D. Carrozzino, F. Fraticelli, M. Fulcheri, and
E. Vitacolonna, “Quality of life in women with gestational dia-
betes mellitus: a systematic review,” Journal of Diabetes
Research, vol. 2017, Article ID 7058082, 12 pages, 2017.
[8] O. Langer, Y. Yogev, O. Most, and E. M. J. Xenakis,
“Gestational diabetes: the consequences of not treating,”
American Journal of Obstetrics and Gynecology, vol. 192,
no. 4, pp. 989–997, 2005.
[9] T. D. Clausen, E. R. Mathiesen, T. Hansen et al., “High preva-
lence of type 2 diabetes and pre-diabetes in adult offspring of
women with gestational diabetes mellitus or type 1 diabetes,”
Diabetes Care, vol. 31, no. 2, pp. 340–346, 2008.
[10] A. Jiwani, E. Marseille, N. Lohse, P. Damm, M. Hod, and J. G.
Kahn, “Gestational diabetes mellitus: results from a survey of
country prevalence and practices,” The Journal of Maternal-
Fetal & Neonatal Medicine, vol. 25, no. 6, pp. 600–610, 2012.
[11] C. R. Pullinger, I. D. Goldfine, S. Tanyolaç et al., “Evidence that
an HMGA1 gene variant associates with type 2 diabetes, body
mass index, and high-density lipoprotein cholesterol in a
Hispanic-American population,” Metabolic Syndrome and
Related Disorders, vol. 12, no. 1, pp. 25–30, 2014.
[12] J. Yan, R. Su, D. Ao, Y.Wang, H.Wang, and H. Yang, “Genetic
variants and clinical relevance associated with gestational dia-
betes mellitus in Chinese women: a case-control study,” The
Journal of Maternal-Fetal & Neonatal Medicine, pp. 1–7, 2017.
[13] M. M. Agarwal, “Gestational diabetes mellitus: an update on
the current international diagnostic criteria,” World Journal
of Diabetes, vol. 6, no. 6, pp. 782–791, 2015.
[14] L. R. Mack and P. G. Tomich, “Gestational diabetes: diagnosis,
classification, and clinical care,” Obstetrics and Gynecology
Clinics of North America, vol. 44, no. 2, pp. 207–217, 2017.
[15] E. Chiefari, B. Arcidiacono, D. Foti, and A. Brunetti, “Gesta-
tional diabetes mellitus: an updated overview,” Journal of
Endocrinological Investigation, vol. 40, no. 9, pp. 899–909,
2017.
[16] L. Kanguru, N. Bezawada, J. Hussein, and J. Bell, “The burden
of diabetes mellitus during pregnancy in low- and middle-
income countries: a systematic review,” Global Health Action,
vol. 7, no. 1, article 23987, 2014.
[17] S. Macaulay, D. B. Dunger, and S. A. Norris, “Gestational dia-
betes mellitus in Africa: a systematic review,” PLoS One, vol. 9,
no. 6, article e97871, 2014.
[18] J. Hirst, C. Raynes-Greenow, and H. Jeffery, “A systematic
review of trends of gestational diabetes mellitus in Asia,” Jour-
nal of Diabetology, vol. 3, no. 3, p. 5, 2012.
[19] G. E. Tutino, W. H. Tam, X. Yang, J. C. N. Chan, T. T. H. Lao,
and R. C. W. Ma, “Diabetes and pregnancy: perspectives from
Asia,” Diabetic Medicine, vol. 31, no. 3, pp. 302–318, 2014.
[20] S. Y. Chu, W. M. Callaghan, S. Y. Kim et al., “Maternal obesity
and risk of gestational diabetes mellitus,” Diabetes Care,
vol. 30, no. 8, pp. 2070–2076, 2007.
[21] A. Vaiserman, “Early-life nutritional programming of type 2
diabetes: experimental and quasi-experimental evidence,”
Nutrients, vol. 9, no. 3, 2017.
[22] I. O. L. Wong, B. J. Cowling, and C. M. Schooling, “Vulnerabil-
ity to diabetes in Chinese: an age–period–cohort analysis,”
Annals of Epidemiology, vol. 25, no. 1, pp. 34–39, 2015.
7Journal of Diabetes Research
[23] X. Jiang, H. Ma, Y. Wang, and Y. Liu, “Early life factors and
type 2 diabetes mellitus,” Journal of Diabetes Research,
vol. 2013, Article ID 485082, 11 pages, 2013.
[24] G. V. Krishnaveni and C. S. Yajnik, “Developmental origins of
diabetes—an Indian perspective,” European Journal of Clinical
Nutrition, vol. 71, no. 7, pp. 865–869, 2017.
[25] The United Nations, “Demographic yearbook 2015,” February
2017, https://unstats.un.org/unsd/demographic/products/dyb
/dyb2015/Table01.pdf.
[26] International Monetary Fund, “World economic outlook data-
base,” August 2017, https://www.imf.org/external/pubs/ft/
weo/2017/01/weodata/index.aspx.
[27] International Diabetes Federation, IDF Diabetes Atlas, 2015.
[28] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and PRISMA
Group, “Preferred reporting items for systematic reviews and
meta-analyses: the PRISMA statement,” International Journal
of Surgery, vol. 8, no. 5, pp. 336–341, 2010.
[29] D. F. Stroup, J. A. Berlin, S. C. Morton et al., “Meta-analysis of
observational studies in epidemiology: a proposal for report-
ing,” JAMA, vol. 283, no. 15, pp. 2008–2012, 2000.
[30] United Nations Statistics Division, “Geographical region and
composition of each region,” January 2017, http://unstats.un
.org/unsd/methods/m49/m49regin.htm#asia.
[31] National Health and Medical Research Council, “NHMRC
additional levels of evidence and grades for recommenda-
tions for developers of guidelines,” March 2017, https://
www.nhmrc.gov.au/_files_nhmrc/file/guidelines/developers/
nhmrc_levels_grades_evidence_120423.pdf.
[32] M. J. Gardner and D. G. Altman, “Confidence intervals rather
than P values: estimation rather than hypothesis testing,” BMJ,
vol. 292, no. 6522, pp. 746–750, 1986.
[33] R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,”
Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986.
[34] J. P. Higgins and S. G. Thompson, Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 (Updated
March 2011), The Cochrane Collaboration, 2011, http://
handbook.cochrane.org.
[35] J. P. T. Higgins and S. G. Thompson, “Quantifying heterogene-
ity in a meta-analysis,” Statistics in Medicine, vol. 21, no. 11,
pp. 1539–1558, 2002.
[36] T. S. Tran, J. E. Hirst, M. A. T. Do, J. M. Morris, and H. E. Jeff-
ery, “Early prediction of gestational diabetes mellitus in Viet-
nam: clinical impact of currently recommended diagnostic
criteria,” Diabetes Care, vol. 36, no. 3, pp. 618–624, 2013.
[37] P. Sunsaneevithayakul, D. Boriboohirunsarn, A. Sutanthavibul
et al., “Risk factor-based selective screening program for gesta-
tional diabetes mellitus in Siriraj Hospital: result from clinical
practice guideline,” Journal of the Medical Association of
Thailand, vol. 86, no. 8, pp. 708–714, 2003.
[38] C. Y. Chou, C. L. Lin, C. K. Yang, W. C. Yang, F. K. Lee, and
M. S. Tsai, “Pregnancy outcomes of Taiwanese women with
gestational diabetes mellitus: a comparison of Carpenter-
Coustan and National Diabetes Data Group Criteria,” Journal
of Women's Health, vol. 19, no. 5, pp. 935–939, 2010.
[39] M. Morikawa, T. Yamada, T. Yamada et al., “Change in
the number of patients after the adoption of IADPSG criteria
for hyperglycemia during pregnancy in Japanese women,”
Diabetes Research and Clinical Practice, vol. 90, no. 3,
pp. 339–342, 2010.
[40] Y.-S. Chong, S. Cai, H. Lin et al., “Ethnic differences trans-
late to inadequacy of high-risk screening for gestational
diabetes mellitus in an Asian population: a cohort study,”
BMC Pregnancy and Childbirth, vol. 14, no. 1, 2014.
[41] S. Liao, J. Mei, W. Song et al., “The impact of the International
Association of Diabetes and Pregnancy Study Groups
(IADPSG) fasting glucose diagnostic criterion on the preva-
lence and outcomes of gestational diabetes mellitus in Han
Chinese women,” Diabetic Medicine, vol. 31, no. 3, pp. 341–
351, 2014.
[42] M. Shang and L. Lin, “IADPSG criteria for diagnosing ges-
tational diabetes mellitus and predicting adverse pregnancy
outcomes,” Journal of Perinatology, vol. 34, no. 2, pp. 100–
104, 2014.
[43] M. Shang, L. Lin, L. Ma, and L. Yin, “Investigation on the
suitability of the International Association of Diabetes and
Pregnancy Study Group diagnostic criteria for gestational
diabetes mellitus in China,” Journal of Obstetrics and
Gynaecology, vol. 34, no. 2, pp. 141–145, 2014.
[44] T. H. Hung and T. T. Hsieh, “The effects of implementing the
International Association of Diabetes and Pregnancy Study
Groups Criteria for diagnosing gestational diabetes on mater-
nal and neonatal outcomes,” PLoS One, vol. 10, no. 3, article
e0122261, 2015.
[45] J. Leng, P. Shao, C. Zhang et al., “Prevalence of gestational dia-
betes mellitus and its risk factors in Chinese pregnant women:
a prospective population-based study in Tianjin, China,” PLoS
One, vol. 10, no. 3, article e0121029, 2015.
[46] J. Luengmettakul, P. Sunsaneevithayakul, and P. Talungchit,
“Pregnancy outcome in women with gestational diabetes
mellitus according to the Carpenter–Coustan criteria in
Thailand,” The Journal of Obstetrics and Gynaecology
Research, vol. 41, no. 9, pp. 1345–1351, 2015.
[47] E. Nobumoto, H. Masuyama, Y. Hiramatsu, T. Sugiyama,
H. Kusaka, and N. Toyoda, “Effect of the new diagnostic cri-
teria for gestational diabetes mellitus among Japanese
women,” Diabetology International, vol. 6, no. 3, pp. 226–
231, 2015.
[48] H. Yang, M. Zhang, H. Zhang et al., “Comparing the diag-
nostic criteria for gestational diabetes mellitus of World
Health Organization 2013 with 1999 in Chinese popula-
tion,” Chinese Medical Journal, vol. 128, no. 1, pp. 125–
127, 2015.
[49] J. R. He, M. Y. Yuan, N. N. Chen et al., “Maternal dietary
patterns and gestational diabetes mellitus: a large prospective
cohort study in China,” British Journal of Nutrition, vol. 113,
no. 08, pp. 1292–1300, 2015.
[50] G. Li, L. Kong, L. Zhang et al., “Early pregnancy maternal lipid
profiles and the risk of gestational diabetes mellitus stratified
for body mass index,” Reproductive Sciences, vol. 22, no. 6,
pp. 712–717, 2015.
[51] S. Peng, L. Liu, X. Zhang et al., “A nested case-control study
indicating heavy metal residues in meconium associate with
maternal gestational diabetes mellitus risk,” Environmental
Health, vol. 14, no. 1, p. 19, 2015.
[52] C. Wang, W. Zhu, Y. Wei, H. Feng, R. Su, and H. Yang, “Exer-
cise intervention during pregnancy can be used to manage
weight gain and improve pregnancy outcomes in women with
gestational diabetes mellitus,” BMC Pregnancy and Childbirth,
vol. 15, no. 1, 2015.
[53] Y. M. Wei, H. X. Yang, W. W. Zhu, H. Y. Yang, H. X. Li, and
A. Kapur, “Effects of intervention to mild GDM on outcomes,”
The Journal of Maternal-Fetal & Neonatal Medicine, vol. 28,
no. 8, pp. 928–931, 2015.
8 Journal of Diabetes Research
[54] H. P. Li, F. H. Wang, M. F. Tao, Y. J. Huang, and W. P. Jia,
“Association between glycemic control and birthweight with
glycated albumin in Chinese women with gestational diabe-
tes mellitus,” Journal of Diabetes Investigation, vol. 7, no. 1,
pp. 48–55, 2016.
[55] Y. M. Wei, J. Yan, and H. X. Yang, “Identification of severe
gestational diabetes mellitus after new criteria used in
China,” Journal of Perinatology, vol. 36, no. 2, pp. 90–94,
2016.
[56] Q. Xu, Z. Y. Gao, L. M. Li et al., “The Association of Maternal
Body Composition and Dietary Intake with the risk of gesta-
tional diabetes mellitus during the second trimester in a cohort
of Chinese pregnant women,” Biomedical and Environmental
Sciences, vol. 29, no. 1, pp. 1–11, 2016.
[57] M. Ye, Y. Liu, X. Cao et al., “The utility of HbA1c for screening
gestational diabetes mellitus and its relationship with adverse
pregnancy outcomes,” Diabetes Research and Clinical Practice,
vol. 114, pp. 43–49, 2016.
[58] X. Yang, B. Hsu-Hage, H. Zhang et al., “Gestational diabetes
mellitus in women of single gravidity in Tianjin City, China,”
Diabetes Care, vol. 25, no. 5, pp. 847–851, 2002.
[59] Z. Fan, H. Yang, X. Gao, H. Lintu, and W. Sun, “Pregnancy
outcome in gestational diabetes,” International Journal of
Gynecology & Obstetrics, vol. 94, no. 1, pp. 12–16, 2006.
[60] H. Yang, Y. Wei, X. Gao et al., “Risk factors for gestational
diabetes mellitus in Chinese women—a prospective study of
16 286 pregnant women in China,” Diabetic Medicine,
vol. 26, no. 11, pp. 1099–1104, 2009.
[61] Y. Wang, M. Nie, W. Li et al., “Association of six single
nucleotide polymorphisms with gestational diabetes mellitus
in a Chinese population,” PLoS One, vol. 6, no. 11, article
e26953, 2011.
[62] F. Zhang, L. Dong, C. P. Zhang et al., “Increasing prevalence of
gestational diabetes mellitus in Chinese women from 1999 to
2008,” Diabetic Medicine, vol. 28, no. 6, pp. 652–657, 2011.
[63] Y. Chang, X. Chen, H. Cui, Z. Zhang, and L. Cheng, “Follow-
up of postpartum women with gestational diabetes mellitus
(GDM),” Diabetes Research and Clinical Practice, vol. 106,
no. 2, pp. 236–240, 2014.
[64] G. Liu, N. Li, S. Sun et al., “Maternal OGTT glucose levels at
26–30 gestational weeks with offspring growth and develop-
ment in early infancy,” BioMed Research International,
vol. 2014, Article ID 516980, 11 pages, 2014.
[65] H. C. Jang, C. H. Yim, K. O. Han et al., “Gestational diabetes
mellitus in Korea: prevalence and prediction of glucose intol-
erance at early postpartum,” Diabetes Research and Clinical
Practice, vol. 61, no. 2, pp. 117–124, 2003.
[66] C. H. Lin, S. F. Wen, Y. H. Wu, and M. J. Huang, “Using
the 100-g oral glucose tolerance test to predict fetal and
maternal outcomes in women with gestational diabetes
mellitus,” Chang Gung Medical Journal, vol. 32, no. 3,
pp. 283–289, 2009.
[67] C. M. Chuang, I. F. Lin, H. C. Horng, Y. H. Hsiao, I. L. Shyu,
and P. Chou, “The impact of gestational diabetes mellitus on
postpartum urinary incontinence: a longitudinal cohort study
on singleton pregnancies,” BJOG: An International Journal of
Obstetrics and Gynaecology, vol. 119, no. 11, pp. 1334–1343,
2012.
[68] S. Park, M. Y. Kim, S. H. Baik et al., “Gestational diabetes is
associated with high energy and saturated fat intakes and
with low plasma visfatin and adiponectin levels independent
of prepregnancy BMI,” European Journal of Clinical Nutrition,
vol. 67, no. 2, pp. 196–201, 2013.
[69] P. Wang, M. C. Lu, C. W. Yu, L. C. Wang, and Y. H. Yan,
“Influence of food intake on the predictive value of the gesta-
tional diabetes mellitus screening test,” Obstetrics & Gynecol-
ogy, vol. 121, no. 4, pp. 750–758, 2013.
[70] S. J. Yang, T. N. Kim, S. H. Baik et al., “Insulin secretion and
insulin resistance in Korean women with gestational diabetes
mellitus and impaired glucose tolerance,” The Korean Journal
of Internal Medicine, vol. 28, no. 3, pp. 306–313, 2013.
[71] G. J. Cho, L. Y. Kim, Y. N. Sung et al., “Secular trends of
gestational diabetes mellitus and changes in its risk factors,”
PLoS One, vol. 10, no. 8, article e0136017, 2015.
[72] J. M. Heo, T. H. Kim, M. H. Hahn et al., “Comparison of the
effects of gestational weight gain on pregnancy outcomes
between non-diabetic and diabetic women,” Obstetrics &
Gynecology Science, vol. 58, no. 6, pp. 461–467, 2015.
[73] Y. Iimura, M. Matsuura, Z. Yao et al., “Lack of predictive
power of plasma lipids or lipoproteins for gestational diabetes
mellitus in Japanese women,” Journal of Diabetes Investiga-
tion, vol. 6, no. 6, pp. 640–646, 2015.
[74] Y. J. Jung, J. Y. Kwon, H. Y. Cho, Y. W. Park, and Y. H. Kim,
“Comparison of the performance of screening test for gesta-
tional diabetes in singleton versus twin pregnancies,” Obstet-
rics & Gynecology Science, vol. 58, no. 6, pp. 439–445, 2015.
[75] B. K. Koo, J. H. Lee, J. Kim, E. J. Jang, and C.-H. Lee, “Preva-
lence of gestational diabetes mellitus in Korea: a national
health insurance database study,” PLoS One, vol. 11, no. 4,
article e0153107, 2016.
[76] R. Ohara, M. Obata-Yasuoka, K. Abe, H. Yagi, H. Hamada,
and H. Yoshikawa, “Effect of hyperemesis gravidarum on
gestational diabetes mellitus screening,” International Jour-
nal of Gynecology & Obstetrics, vol. 132, no. 2, pp. 156–
158, 2016.
[77] J. S. Park, D. W. Kim, J. Y. Kwon, Y. W. Park, Y. H. Kim,
and H. Y. Cho, “Development of a screening tool for pre-
dicting adverse outcomes of gestational diabetes mellitus: a
retrospective cohort study,” Medicine, vol. 95, no. 1, article
e2204, 2016.
[78] M. Shimodaira, T. Yamasaki, and T. Nakayama, “The associa-
tion of maternal ABO blood group with gestational diabetes
mellitus in Japanese pregnant women,” Diabetes & Metabolic
Syndrome: Clinical Research & Reviews, vol. 10, no. 2,
pp. S102–S105, 2016.
[79] D. Boriboonhirunsarn, P. Sunsaneevithayakul, and
M. Nuchangrid, “Incidence of gestational diabetes mellitus
diagnosed before 20 weeks of gestation,” Journal of the Medical
Association of Thailand, vol. 87, no. 9, pp. 1017–1021, 2004.
[80] C. Punthumapol and P. Tekasakul, “50 grams glucose chal-
lenge test for screening of gestational diabetes mellitus in each
trimester in potential diabetic pregnancy,” Journal of the Med-
ical Association of Thailand, vol. 91, no. 6, pp. 787–793, 2008.
[81] P. Ruangvutilert, P. Chaemsaithong, K. Ruangrongmorakot,
S. Kanokpongsakdi, and P. Sunsaneevithayakul, “Develop-
ment of a modified 100-gram oral glucose tolerance test for
diagnosis of gestational diabetes mellitus and its diagnostic
accuracy,” Journal of the Medical Association of Thailand,
vol. 93, no. 10, pp. 1121–1127, 2010.
[82] P. C. Tan, J. N. Chai, L. P. Ling, and S. Z. Omar, “Maternal
hemoglobin level and red cell indices as predictors of gesta-
tional diabetes in a multi-ethnic Asian population,” Clinical
9Journal of Diabetes Research
and Experimental Obstetrics & Gynecology, vol. 38, no. 2,
pp. 150–154, 2011.
[83] S. Srichumchit, S. Luewan, and T. Tongsong, “Outcomes of
pregnancy with gestational diabetes mellitus,” International
Journal of Gynecology & Obstetrics, vol. 131, no. 3, pp. 251–
254, 2015.
[84] C. L. DeSisto, S. Y. Kim, and A. J. Sharma, “Prevalence esti-
mates of gestational diabetes mellitus in the United States,
pregnancy risk assessment monitoring system (PRAMS),
2007–2010,” Preventing Chronic Disease, vol. 11, article E104,
2014.
[85] C. Chamberlain, G. Joshy, H. Li, J. Oats, S. Eades, and
E. Banks, “The prevalence of gestational diabetes mellitus
among aboriginal and Torres Strait Islander women in
Australia: a systematic review and meta-analysis,” Diabetes/
Metabolism Research and Reviews, vol. 31, no. 3, pp. 234–
247, 2015.
[86] C. E. Eades, D. M. Cameron, and J. M. M. Evans, “Prevalence
of gestational diabetes mellitus in Europe: a meta-analysis,”
Diabetes Research and Clinical Practice, vol. 129, pp. 173–
181, 2017.
[87] L. Yuen and V. W. Wong, “Gestational diabetes mellitus: chal-
lenges for different ethnic groups,” World Journal of Diabetes,
vol. 6, no. 8, pp. 1024–1032, 2015.
[88] D. J. P. Barker, “The origins of the developmental origins the-
ory,” Journal of Internal Medicine, vol. 261, no. 5, pp. 412–417,
2007.
[89] National Diabetes Data Group, “Classification and diagnosis
of diabetes mellitus and other categories of glucose intoler-
ance,” Diabetes, vol. 28, no. 12, pp. 1039–1057, 1979.
[90] M. W. Carpenter and D. R. Coustan, “Criteria for screening
tests for gestational diabetes,” American Journal of Obstetrics
and Gynecology, vol. 144, no. 7, pp. 768–773, 1982.
[91] American Diabetes Association, “Gestational diabetes melli-
tus,” Diabetes Care, vol. 23, Supplement 1, pp. S77–S90, 2004.
[92] World Health Organization, Definition, Diagnosis and Clas-
sification of Diabetes Mellitus and its Complications. Part 1:
Diagnosis and Classification of Diabetes Mellitus, Geneva,
1999.
[93] International Association of Diabetes and Pregnancy Study
Groups Consensus Panel, B. E. Metzger, S. G. Gabbe et al.,
“International association of diabetes and pregnancy study
groups recommendations on the diagnosis and classification
of hyperglycemia in pregnancy,” Diabetes Care, vol. 33, no. 3,
pp. 676–682, 2010.
[94] J. Trujillo, A. Vigo, B. B. Duncan et al., “Impact of the
International Association of Diabetes and Pregnancy Study
Groups criteria for gestational diabetes,” Diabetes Research
and Clinical Practice, vol. 108, no. 2, pp. 288–295, 2015.
[95] L. Hartling, D. M. Dryden, A. Guthrie, M. Muise,
B. Vandermeer, and L. Donovan, “Diagnostic thresholds for
gestational diabetes and their impact on pregnancy outcomes:
a systematic review,”Diabetic Medicine, vol. 31, no. 3, pp. 319–
331, 2014.
[96] International Association of Diabetes & Pregnancy Study
Groups (IADPSG) Consensus Panel Writing Group and the
Hyperglycemia & Adverse Pregnancy Outcome (HAPO)
Study Steering Committee, B. E. Metzger, S. G. Gabbe et al.,
“The diagnosis of gestational diabetes mellitus: new paradigms
or status quo?,” The Journal of Maternal-Fetal & Neonatal
Medicine, vol. 25, no. 12, pp. 2564–2569, 2012.
[97] G. T. C. Ko, J. C. N. Chan, V. T. F. Yeung, C.-C. Chow, L. W.
W. Tsang, and C. S. Cockram, “A low socio-economic status is
an additional risk factor for glucose intolerance in high risk
Hong Kong Chinese,” European Journal of Epidemiology,
vol. 17, no. 3, pp. 289–295, 2001.
[98] S. Bo, G. Menato, C. Bardelli et al., “Low socioeconomic status
as a risk factor for gestational diabetes,” Diabetes & Metabo-
lism, vol. 28, no. 2, pp. 139-140, 2002.
[99] Y. Zhu and C. Zhang, “Prevalence of gestational diabetes and
risk of progression to type 2 diabetes: a global perspective,”
Current Diabetes Reports, vol. 16, no. 1, p. 7, 2016.
10 Journal of Diabetes Research
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
